HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer.

Abstract
Cancer-testis antigens (CTA), such as NY-ESO-1, MAGE-A1, and MAGE-A3, are immunogenic proteins encoded by genes, which are normally expressed only in male germ cells but are activated by ill-defined epigenetic mechanisms in human tumors, including lung cancers. Previously, we reported induction of these CTAs in cancer cells, but not normal cells, by DNA-demethylating agents and histone deacetylase inhibitors using clinically achievable exposure conditions. In the present study, we evaluated chromatin alterations associated with repression/activation of cancer-testis genes in lung cancer cells to further develop gene-induction regimens for cancer immunotherapy. Repression of NY-ESO-1, MAGE-A1, and MAGE-A3 coincided with DNA hypermethylation, recruitment, and binding of polycomb-group proteins, and histone heterochromatin modifications within the promoters of these genes. Derepression coincided with DNA demethylation, dissociation of polycomb proteins, and presence of euchromatin marks within the respective promoters. Short hairpin RNAs were used to inhibit several histone methyltransferases (KMT) and histone demethylases (KDM) that mediate histone methylation and repress gene expression. Knockdown of KMT6, KDM1, or KDM5B markedly enhanced deoxyazacytidine (DAC)-mediated activation of these cancer-testis genes in lung cancer cells. DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6 knockdown. Following DAC-DZNep exposure, lung cancer cells were specifically recognized and lysed by allogeneic lymphocytes expressing recombinant T-cell receptors recognizing NY-ESO-1 and MAGE-A3. Combining DNA-demethylating agents with compounds, such as DZNep, that modulate histone lysine methylation may provide a novel epigenetic strategy to augment cancer-testis gene expression as an adjunct to adoptive cancer immunotherapy.
AuthorsMahadev Rao, Nachimuthu Chinnasamy, Julie A Hong, Yuwei Zhang, Mary Zhang, Sichuan Xi, Fang Liu, Victor E Marquez, Richard A Morgan, David S Schrump
JournalCancer research (Cancer Res) Vol. 71 Issue 12 Pg. 4192-204 (Jun 15 2011) ISSN: 1538-7445 [Electronic] United States
PMID21546573 (Publication Type: Journal Article)
Chemical References
  • Antigens, Neoplasm
  • CTAG1B protein, human
  • Chromatin
  • Enzyme Inhibitors
  • Histones
  • MAGEA1 protein, human
  • MAGEA3 protein, human
  • Melanoma-Specific Antigens
  • Membrane Proteins
  • Neoplasm Proteins
  • Histone Methyltransferases
  • Histone-Lysine N-Methyltransferase
  • Lysine
Topics
  • Antigens, Neoplasm (genetics)
  • Cell Line, Tumor
  • Chromatin (chemistry)
  • DNA Methylation
  • Enzyme Inhibitors (pharmacology)
  • Gene Expression Profiling
  • Histone Methyltransferases
  • Histone-Lysine N-Methyltransferase (antagonists & inhibitors)
  • Histones (metabolism)
  • Humans
  • Immunotherapy, Adoptive
  • Lung Neoplasms (immunology, therapy)
  • Lysine (metabolism)
  • Melanoma-Specific Antigens (genetics)
  • Membrane Proteins (genetics)
  • Methylation
  • Neoplasm Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: